Chloroquine
| 證據等級: L5 | 預測適應症: 4 個 |
目錄
Chloroquine: From Malaria to RF-Positive Polyarticular Juvenile Idiopathic Arthritis
One-Sentence Summary
Chloroquine is a classic antimalarial agent and disease-modifying antirheumatic drug (DMARD), historically used to treat malaria and certain autoimmune conditions including rheumatoid arthritis. The TxGNN model predicts it may be effective for Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis (RF+ pJIA), with 0 clinical trials and 2 publications currently providing indirect supporting evidence for this specific subtype.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Malaria (no Philippines registration on file) |
| Predicted New Indication | Rheumatoid factor-positive polyarticular juvenile idiopathic arthritis |
| TxGNN Prediction Score | 99.41% |
| Evidence Level | L4 |
| Philippines Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from this evidence package. Based on established pharmacology, chloroquine is a lysosomotropic compound that interferes with endosomal/lysosomal function. Its immune-modulating effects include: (1) inhibition of TLR7/TLR9 innate signaling, which reduces type I interferon and pro-inflammatory cytokine production; (2) impairment of lysosomal acidification, which disrupts MHC class II antigen presentation and downstream T-cell activation; and (3) direct suppression of TNF-α, IL-1β, and IL-6, the core cytokines driving chronic synovitis.
RF-positive polyarticular JIA is the JIA subtype most closely resembling adult seropositive rheumatoid arthritis — both are driven by B-cell autoantibody production (rheumatoid factor), sustained synovial inflammation, and progressive joint destruction. Chloroquine’s multi-target immune profile mechanistically overlaps with the pathogenesis of this subtype, which is why the TxGNN model assigns a high prediction score.
It is important to note, however, that the analogue drug hydroxychloroquine (HCQ) — not chloroquine — is more commonly referenced in the JIA literature. No clinical studies directly evaluate chloroquine in RF+ polyarticular JIA specifically. Additionally, the broader evidence pack reveals stronger historical support for chloroquine in the closely related indication of juvenile chronic polyarthritis (Evidence Level L3; see PMID 1688268, a comparative trial of chloroquine vs. sulphasalazine in JCA), suggesting the TxGNN model is capturing a mechanistically coherent signal across related arthritis subtypes, even though RF+ pJIA itself lacks direct clinical data.
Clinical Trial Evidence
Currently no related clinical trials registered for this specific indication.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 24334641 | 2014 | Prospective Observational | The Journal of Rheumatology | Long-term real-world experience with leflunomide in JIA patients; provides context for DMARD use in JIA, but does not directly evaluate chloroquine in this subtype |
| 8627446 | 1996 | Case Report/Series | The Journal of Pediatrics | Two RF+ polyarticular JRA patients developed MTX-induced accelerated nodulosis; nodule progression was arrested by addition of hydroxychloroquine — indirect evidence supporting antimalarial use in this specific JIA subtype |
Philippines Market Information
Chloroquine is currently not registered or marketed in the Philippines. No license records are available in the FDA Philippines database.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (RF+ polyarticular JIA) lacks any direct clinical trial evidence for chloroquine and is supported by only 2 indirectly relevant publications. Furthermore, chloroquine is not registered in the Philippines, creating a significant regulatory barrier before any clinical application could be considered.
To proceed, the following is needed:
- MOA data gap closure: Retrieve mechanism of action details from DrugBank (DB00608) to support pharmacological plausibility analysis
- Safety data gap closure: Download and parse the TFDA package insert PDF to obtain warnings, contraindications, and drug interactions — currently classified as a Blocking data gap
- Direct clinical evidence: Identify or commission studies specifically evaluating chloroquine (not only HCQ) in RF+ polyarticular JIA; existing evidence is based on the broader antimalarial class
- Analogue comparison: Evaluate whether hydroxychloroquine, which has a comparable mechanism and substantially broader evidence base in JIA, could serve as a more feasible repurposing candidate for this indication
- Regulatory pathway: If clinical development is pursued, a Philippines FDA registration strategy for chloroquine must be established prior to any interventional study
- Cross-indication review: The related indications in this pack — particularly juvenile chronic polyarthritis (L3 evidence, “Proceed with Guardrails”) — carry meaningfully stronger direct support for chloroquine and may represent a more actionable starting point for repurposing evaluation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.